Potential New ALS Treatment Blocks Inflammation to Restore Neuronal Connections

A study led by Professor Chantelle Sephton from Université Laval's Faculty of Medicine has identified a crucial connection between the structural changes in neurons and the immune response in individuals with amyotrophic lateral sclerosis (ALS). The research, conducted on a genetically modified mouse model, reveals that alterations in upper motor neurons precede the onset of ALS symptoms.

The study, published in Acta Neuropathologica Communications, suggests that these morphological changes act as a signal triggering the activation of microglia and astrocytes, the immune cells of the central nervous system. While initially protective, prolonged presence of these immune cells becomes toxic to neurons, resulting in diminished synaptic connections between motor neurons in the brain and spinal cord. This cascade effect ultimately leads to muscle atrophy and loss of motor function.

Focusing on the correlation between symptoms and the immune response, the research team explored a potential solution: a semi-synthetic drug based on Withaferin A, derived from the Ashwagandha plant, a staple in traditional Indian medicine for millennia. This drug demonstrated the ability to block inflammation, allowing motor neurons to revert to a more normal state.

Remarkably, the drug facilitated neuron regeneration in the absence of activated immune cells. Motor neuron dendrites began to grow and re-establish connections, thereby increasing the number of synapses between motor neurons and muscles. The findings indicate a promising avenue for improving ALS symptoms, regardless of whether the disease is familial or sporadic, given their common association with inflammation.

Moreover, this approach targeting inflammation to restore neuronal connections holds potential applications beyond ALS, extending to other neurodegenerative diseases like Alzheimer's, where inflammation also plays a pivotal role.